50 results on '"Sellers, William R"'
Search Results
2. Are CRISPR Screens Providing the Next Generation of Therapeutic Targets?
3. A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts
4. Abstract 1097: FGFR2 in-frame indels: A novel targetable alteration in intrahepatic cholangiocarcinoma
5. Abstract 1770: A new DOT1L inhibitor with in vivo activity in mouse models of MLL-translocated leukemia
6. Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockade
7. Abstract 3227: CLIFF, a bioinformatics software tool to explore molecular differences between two sets of cancer cell lines
8. Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201
9. Abstract DDT01-04: Pharmacological profile and anti-tumor properties of LXH254, a highly selective RAF kinase inhibitor
10. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF
11. Abstract 2098: NVP-FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of HCC
12. High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells
13. Abstract 1224: Insights into the mechanism of action of NVP-HDM201, a differentiated and versatile Next-Generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials
14. Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition
15. Abstract 2930: Global chromatin profiling reveals NSD2 mutation in pediatric ALL
16. Inhibiting Tankyrases Sensitizes KRAS-Mutant Cancer Cells to MEK Inhibitors via FGFR2 Feedback Signaling
17. An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
18. Abstract PR01: Global chromatin profiling identifies NSD2 mutations in pediatric acute lymphoblastic leukemia
19. Abstract SY17-03: Targeting BRAF and PI3′-kinase signaling for therapy of melanoma.
20. Abstract PL01-01: The genetic basis for cancer therapeutics
21. Abstract 3853: TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches
22. A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients
23. PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling
24. The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma Cells
25. Abstract DD01-04: NVP-BKM120: A selective inhibitor of type I PI3 kinases
26. Abstract 4290: The smoothened antagonist NVP-LDE225 targets stroma and cancer stem cells in primary human pancreatic tumor xenografts
27. Abstract 4497: NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials, shows significant antitumor activity in xenograft and primary tumor models
28. Abstract 4498: Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials
29. An Oncogenic Role for ETV1 in Melanoma
30. Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney
31. PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
32. Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
33. Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma
34. A Smac Mimetic Rescue Screen Reveals Roles for Inhibitor of Apoptosis Proteins in Tumor Necrosis Factor-α Signaling
35. TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer
36. Signal Transducer and Activator of Transcription 3 Is Required for the Oncogenic Effects of Non–Small-Cell Lung Cancer–Associated Mutations of the Epidermal Growth Factor Receptor
37. From Integrated Genomics to Tumor Lineage Dependency
38. Seventeenth Annual Pezcoller Symposium: Molecular Understanding of Solid Tumors
39. Epidermal Growth Factor–Independent Transformation of Ba/F3 Cells with Cancer-Derived Epidermal Growth Factor Receptor Mutants Induces Gefitinib-Sensitive Cell Cycle Progression
40. Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis
41. Activating Mutations of the Noonan Syndrome-AssociatedSHP2/PTPN11Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
42. Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells
43. Overexpression, Amplification, and Androgen Regulation of TPD52 in Prostate Cancer
44. An Integrated View of Copy Number and Allelic Alterations in the Cancer Genome Using Single Nucleotide Polymorphism Arrays
45. Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.
46. Editor's Note: Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells.
47. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling.
48. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
49. Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP.
50. Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.